Skip to content

The Kaia Back Pain Intervention for Self-management of Low Back Pain

The Kaia Back Pain Intervention for Self-management of Low Back Pain - a Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04290078
Acronym
BACKSPIN
Enrollment
184
Registered
2020-02-28
Start date
2020-12-01
Completion date
2021-08-01
Last updated
2020-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Brief summary

The study aims to evaluate outcomes of the use of Kaia Study app (software program application for self-management of low-back pain) on back pain among adults with non-specific subacute and chronic low back pain based on change in pain intensity, physical functioning, quality of life (PROMIS-10) based on self-reported information from baseline to study end as compared to a control group.

Detailed description

This is a two-arm, parallel assignment, open-label, randomized control trial comparing back pain outcomes in an intervention group (MPT using the Kaia app) to those of a control group (usual care without restrictions on treatment). It is designed to enroll up to 184 participants. The treatment period will last for 90 days. This includes the randomization assignment and follow-up evaluations at 30 days, 60 days, and 90 days post-randomization. After pre-screening and informed consent activities are completed, the study will be conducted using electronic patient reported outcomes (ePROs); participants can complete all study tasks at home by means of internet-enabled devices. Participants assigned to the intervention group will implement Kaia's exercise regimen using their personal mobile devices. The control group will receive usual care without restrictions and will be provided with internet-based information about treatment of non-specific back pain, including handouts depicting typical home-based exercises as recommended by American Academy of Orthopedic Surgeons.

Interventions

DEVICEKaia Back Pain Study App

Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.

OTHERUsual Care

Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth

Sponsors

Brigham and Women's Hospital
CollaboratorOTHER
Kaia Health Software
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Between 22 and 75 years old 2. Able to speak, read, and understand English 3. Smartphone user with a compatible device, built-in camera, and internet access at home 4. Pain intensity ≥4/10 on Numeric Rating Scale (NRS) for low back pain, on average, in the week prior to screening 5. Low back pain diagnosis with duration ≥1 month and \<12 months (i.e., non-specific subacute or chronic back pain) 6. Willingness and capable of providing Informed Consent to use the Kaia Study app and participate in all assessments associated with this clinical study

Exclusion criteria

1. Referral or plans for surgery, chiropractic care, acupuncture, injections or other treatment for low back pain in the next 1 month following screening 2. Self-reported prior subscription to Kaia app or plans to participate in any other investigational trials or protocols for low back pain within 90 days 3. Known pregnancy at screening or plans to become pregnant during study. 4. Prior back surgery or current workers compensation case or litigation related to back pain 5. Self-reported ongoing use of opioids for conditions other than back pain within 30 days prior to screening 6. If taking opioid or NSAID medication for back pain, changes in dosing or type of medications used for analgesic regimen within 30 days prior to screening 7. Use of opioids greater than the following daily doses: oxycodone \>20 mg per day, morphine \> 30 mg per day, hydrocodone \> 30 mg per day, or tramadol \> 300 mg per day within 30 days prior to screening 8. Self-reported history of substance abuse within 1 year 9. Diagnosis of specific underlying cause of back pain (e.g., known spinal fracture, spinal tumor, spinal infection, disc herniation, spinal stenosis) 10. Severe or unstable medical condition (e.g., unstable cardiac disease, active infection, stroke with residual neuromuscular effects, paralysis, gait imbalance, or history of recent recurrent falls)

Design outcomes

Primary

MeasureTime frameDescription
Numerical Rating ScaleChange from baseline NRS at 90 daysPain Intensity (NRS-11, 0 no pain to 10 Severe pain)

Secondary

MeasureTime frameDescription
Patient-Reported Outcomes Measurement Information System 10-Question Short Form (PROMIS-10)baseline (day 0), day 30, day 60 and day 90Quality of Life and overall Health Status (scores are transformed to t score distributions with a mean of 50 and standard deviation of 10. A higher score indicates better health)
Perceived Treatment Helpfulnessbaseline (day 0), day 30, day 60 and day 90Feedback on the mobile medical application (5-Point Likert Scales ranging from 1 lowest satisfaction to 5 highest satisfaction)
Pain Catastrophizing Scalebaseline (day 0) and at day 90Quantify individual's pain catastrophizing (scored from 0 no catastrophizing to 52 worst possible catastrophizing)
Satisfaction and perceived treatment helpfulnessStudy End at day 90Feedback on the mobile medical application (5-Point Likert Scales ranging from 1 lowest satisfaction to 5 highest satisfaction)
Oswestry Disability Indexbaseline (day 0), day 30, day 60 and day 90Measure of Disability in Low Back Pain ( Scale from 0% no disability no to 100% worst possible disability )
Change in concomitant medication usebaseline (day 0), day 15, day 30, day 45, day 60, day 75 and day 90Record of intaken concomitant analgetic medication (number of uses)
Number of Adverse Eventsbaseline (day 0), day 15, day 30, day 45, day 60, day 75 and day 90Absolute number of untoward medical occurrences
Number of Device Deficienciesbaseline (day 0), day 15, day 30, day 45, day 60, day 75 and day 90Absolute number of untoward technical occurrences
Health care utilisationbaseline (day 0), day 30, day 60 and day 90Use of services by persons for the purpose of preventing and curing health problems (type and number of times utilized)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026